Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.
Faculty Thomas E Hutson, DO, PharmD
Director, GU Oncology Program
Co-Director, Urologic Cancer Research and Treatment Center
Texas Oncology
Charles A Sammons Cancer Center
Baylor University Medical Center
Professor of Medicine
Texas A&M HSC College of Medicine
Dallas, Texas
Rana R McKay, MD
Professor of Medicine and Urology
Associate Director, Clinical Research
Co-Lead, Genitourinary Program
Moores Cancer Center
University of California San Diego
San Diego, California
Tian Zhang, MD, MHS
Associate Professor
Director of Clinical Research
Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Associate Director for Clinical Research
Simmons Comprehensive Cancer Center
Dallas, Texas
Moderator Sumanta Kumar Pal, MD
Professor and Vice Chair of Academic Affairs
Department of Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, California
This activity is supported by educational grants from Bristol Myers Squibb, Eisai Inc, and Exelixis Inc.
MODULE 1: Immunotherapeutic Strategies for Localized and Metastatic Clear Cell Renal Cell Carcinoma (RCC)
Available efficacy and safety findings from the Phase III KEYNOTE-564 trial comparing pembrolizumab to placebo as adjuvant treatment for patients with clear cell RCC at increased risk of recurrence after nephrectomy; FDA approval and current role
Ongoing research studies, such as NESCIO, WINSHIP4955-20 and NAPSTER, assessing immune checkpoint inhibitor (ICI)-based combinations in the neoadjuvant setting for localized RCC
Key factors, such as risk classification, age and performance status, histology, prior neoadjuvant or adjuvant therapy, number and location of metastases, and symptomatology, influencing the selection of first-line therapy for patients with newly diagnosed metastatic RCC
Clinical trial database supporting the use of nivolumab/ipilimumab, pembrolizumab/axitinib, nivolumab/cabozantinib and pembrolizumab/lenvatinib for treatment-naïve advanced RCC; appropriate selection of patients to receive the different regimens
Major efficacy and safety outcomes from the Phase III COSMIC-313 trial of nivolumab/ipilimumab/cabozantinib versus nivolumab/ipilimumab for patients with previously untreated, intermediate- or poor-risk advanced RCC; clinical role, if any
MODULE 2: Optimal Management of Relapsed/Refractory (R/R) RCC
Rational sequencing of available therapies for RCC progressing on front-line treatment; clinical and patient-specific factors affecting decision-making in this setting
Published research findings with available agents and regimens commonly employed in the R/R setting
Design, eligibility criteria and key efficacy and safety findings from the Phase III TiNivo-2 study evaluating tivozanib in combination with nivolumab versus tivozanib monotherapy for patients with progressive RCC after treatment with an ICI
Implications of TiNivo-2 results for ICI rechallenge and for tivozanib monotherapy
Findings from the Phase III CheckMate 67T study demonstrating noninferior pharmacokinetics and objective response rate with subcutaneous versus intravenous nivolumab for previously treated advanced RCC; clinical implications
Other promising novel agents and strategies under investigation for advanced clear cell RCC
MODULE 3: Role of HIF-2α Inhibitors in the Treatment of Sporadic and von Hippel-Lindau (VHL)-Associated RCC
Biological rationale for targeting HIF-2α in patients with advanced RCC; mechanism of action of belzutifan
Published findings from the Phase III LITESPARK-005 study of belzutifan for patients with advanced clear cell RCC that has progressed after a PD-1 or PD-L1 checkpoint inhibitor and VEGF tyrosine kinase inhibitor (TKI) therapy
FDA approval of belzutifan and clinical role for patients with sporadic RCC
Spectrum, frequency, severity and optimal management of toxicities associated with belzutifan
Rationale for and available data with belzutifan in combination with other systemic therapies for patients with RCC, such as VEGFR TKIs and ICIs
Ongoing Phase III trials, such as LITESPARK-011, LITESPARK-012 and LITESPARK-022, evaluating belzutifan combinations in the adjuvant and advanced disease settings
Biology and proportion of patients with VHL-associated RCC; available data with and role of belzutifan in treatment for this population
MODULE 4: Current and Future Care of Patients with Non-Clear Cell RCC
Pathophysiology, biology and incidence of various non-clear cell RCC subtypes
Published research findings with and clinical role of TKI monotherapy (eg, sunitinib, cabozantinib) and combination strategies (eg, pembrolizumab/lenvatinib, cabozantinib/nivolumab) for patients with non-clear cell RCC
Design, eligibility criteria and key efficacy and safety findings from the Phase II KEYNOTE-B61 trial evaluating pembrolizumab in combination with lenvatinib as first-line treatment for patients with advanced non-clear cell RCC; recent label update for lenvatinib and implications for clinical management
Mechanism of action of zanzalintinib; similarities and differences between zanzalintinib and cabozantinib
Design, eligibility criteria and key endpoints of the Phase III STELLAR-304 trial assessing zanzalintinib/nivolumab versus sunitinib as first-line treatment for non-clear cell RCC; anticipated completion date
Other promising novel agents and strategies under investigation for non-clear cell RCC
Target Audience
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of renal cell carcinoma.
Learning Objectives
Upon completion of this activity, participants should be able to
Evaluate recently presented data with adjuvant anti-PD-1/PD-L1 antibody therapy for patients with renal cell carcinoma (RCC) at high risk for recurrence after nephrectomy, and consider the current role of this treatment strategy.
Appraise available clinical trial data evaluating anti-PD-1/PD-L1 antibody/multikinase inhibitor combinations for previously untreated metastatic RCC (mRCC), and counsel patients regarding the risks and benefits of these novel regimens.
Review the biological rationale underlying the investigation of anti-PD-1/anti-CTLA-4 combination therapy as first-line treatment for patients with mRCC, and appreciate long-term research findings documenting the effectiveness of this approach.
Assess recently presented clinical trial results with anti-PD-1/PD-L1 antibodies administered as a subcutaneous injection for patients with mRCC, and reflect on the potential benefits of this emerging therapeutic strategy.
Understand the biological rationale for exploiting HIF-2α in patients with von Hippel-Lindau-associated and sporadic RCC, and consider the current role of available inhibitors.
Develop a rational therapeutic approach to the sequencing of systemic therapies for patients with advanced RCC that progresses on first-line treatment, incorporating multikinase inhibitors, HIF-2α inhibitors, immunotherapeutic agents and other strategies.
Appreciate published research findings evaluating the use of available and investigational agents for patients with non-clear cell RCC, and consider the applicability of these strategies in clinical care.
Recall available and emerging data with other novel and investigational agents and strategies in testing for RCC, and as applicable, refer eligible patients for clinical trial participation.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.
FACULTY
The following faculty reported relevant financial relationships with ineligible entities:
MODERATOR —
Dr Pal — Travel Support: CRISPR Therapeutics, EverImmune, Exelixis Inc, Ipsen Biopharmaceuticals Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Eisai Inc, and Exelixis Inc.
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600
Meeting Room
Golden Gate Ballroom — Salon A (B2 Level)
Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Center, where the 2025 ASCO Genitourinary Cancers Symposium is taking place.
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of renal cell carcinoma.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.
NOTICE: Registration for this event is independent of registration for the 2025 ASCO Gastrointestinal Cancers Symposium.
IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
Not an official event of the 2025 ASCO® Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
